SAN FRANCISCO--(BUSINESS WIRE)--Great Basin Corporation, a privately-held molecular diagnostics company developing sample-to-result solutions, today presented initial data of its Candida assay during the Clinical Mycology—Diagnosis, Treatment and Epidemiology (Division F) session at the American Society of Microbiology General Meeting in San Francisco. Currently under development, the assay can detect the most medically relevant Candida species within an hour from blood cultures taken from patients with fungal bloodstream infections (BSI), speeding diagnosis and appropriate treatment for better patient outcomes.
Candidemia constitutes the fourth leading cause of hospital acquired BSI in the United States. Immuno-compromised patients, including transplant, HIV-infected, and chemotherapy patients, are at particularly high risk of fungal infections.
“We are very pleased about the growing body of data that demonstrates the efficacy of Great Basin’s technology,” said Ryan Ashton, president and CEO, Great Basin Corporation. “Great Basin is focused on developing cost-effective tests that markedly change the way clinicians diagnose the most virulent hospital acquired infections, such as Candida. We look forward to expanding our menu of available assays to support the continued adoption of our platform.”
Three additional posters featuring Great Basin’s technology were presented today during the Detection of C. difficile (Division C) session, including:
- Poster #2237 | Performance of the Portrait Toxigenic C. difficile Assay Compared to the BD GeneOhm C.diff PCR Assay and Toxigenic Culture for Diagnosing Clostridium difficile - Presented by Gerald Denys, Ph.D, Indiana University Health Pathology Laboratories
- Poster # 2240 | Multicenter clinical evaluation of the Portrait Toxigenic C. difficile Assay for detection of toxigenic C. difficile directly from clinical specimens - Presented by Nathan A. Ledeboer, PhD, Assistant Professor of Pathology at the Medical College of Wisconsin
- Poster # 2238 | Clinical Comparison of Great Basin Corporation’s Portrait Toxigenic Clostridium difficile Assay and Toxigenic Bacterial Culture - Presented by Trenda Barney, Primary Children’s Medical Center, Salt Lake City, Utah
In May, Great Basin received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its first molecular diagnostic test, which detects Clostridium difficile (C. diff), one of the most common and deadly hospital-acquired infections. The company also released this assay as a European CE-IVD product under the European Directive 98/79/EC on In Vitro Diagnostic Medical Devices. The test is being marketed in both the U.S. and the EU.
The company’s easy-to-use integrated cartridge system allows for more accurate and information-rich detection of infectious diseases, allowing providers to diagnose and define a clear treatment path sooner for improved patient outcomes, shorter hospital stays and significant cost savings. The company’s goal is to deliver assays that can be performed in a CLIA-rated waived or moderately complex laboratory at a lower cost than other molecular diagnostic solutions.
Great Basin’s technology entails an integrated disposable cartridge containing all necessary reagents and an inexpensive bench-top analyzer that executes the assay, interprets the results and provides electronic output to the clinician. The platform has several key advantages over other molecular solutions:
- True sample-to-result with no more than two to three hands-on steps
- On-demand testing; no batching of tests that delay results
- Multiplexes up to 64 distinct targets in a single assay
- Results in under an hour, depending on the target of interest
About Great Basin Corporation
Great Basin Corporation is a privately-held molecular diagnostics company that commercializes breakthrough, chip-based technologies. The company is dedicated to the development of simple, yet powerful, sample-to-result technology and products that provide fast, multiple-pathogen diagnoses of infectious diseases. By providing more diagnostic data per sample, healthcare providers are able to treat patients with the right medication sooner, improving outcomes and reducing costs. The company’s vision is to make molecular diagnostic testing so simple and cost-effective that every patient will be tested for every serious infection, reducing misdiagnoses and significantly limiting the spread of infectious disease. More information can be found on the company’s website at www.gbscience.com.